IO Biotech Announces First Patient Dosed In Investigator-Initiated Phase 1 Trial At University Of California Davis Comprehensive Cancer Center
Portfolio Pulse from Benzinga Newsdesk
IO Biotech has announced that the first patient has been dosed in an investigator-initiated Phase 1 trial at the University of California Davis Comprehensive Cancer Center.
July 28, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IO Biotech's Phase 1 trial has begun with the first patient being dosed. This could potentially lead to positive developments for the company.
The initiation of a Phase 1 trial is a significant step in the development of a new drug or treatment. This news indicates progress in IO Biotech's research and development efforts, which could potentially lead to positive outcomes for the company and its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100